LB Pharmaceuticals Reports Q3 2025 Results and Provides Trial Updates

LB PHARMACEUTICALS INC

2025-Q3 EPS reported -$6.26 vs consensus -$0.46 ▼ miss (-1248.8%)

Net loss narrowed to $3.6M in Q3 2025 from $14.2M in Q3 2024.
Raised $327.8M in upsized IPO at $15.00 per share in September 2025.
Plans to initiate Phase 3 schizophrenia trial with ~460 patients in Q1 2026, topline expected H2 2027.
Appointed William Kane and Rekha Hemrajani to Board, James Rawls as SVP of Regulatory Affairs.
Cash position of $314.5M expected to fund operations into Q2 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.